Merck enters 2026 with $65.0 billion of annual sales, a world-leading oncology franchise and substantial R&D resources. Its central strength—KEYTRUDA—is also its largest concentration risk. New launches, vaccines and Animal Health provide diversification, but Merck must accelerate portfolio renewal before future exclusivity losses reshape its economics.
For how Merck makes money, read our Merck Business Model 2026.
Strengths
1. KEYTRUDA’s oncology leadership
KEYTRUDA generated $31.64 billion in 2025, up 7%. Its broad role across cancer indications gives Merck exceptional oncology scale, clinical-development expertise and commercial reach.
2. Large innovation investment
Merck invested approximately $15.8 billion in R&D in 2025, around 24% of sales. This financial capacity supports a broad pipeline and extensive lifecycle-development programs.
3. Emerging new growth products
WINREVAIR reached $1.44 billion, CAPVAXIVE $759 million and Welireg $716 million in 2025. Their rapid growth demonstrates that newer franchises are beginning to diversify the portfolio.
4. Diversified Animal Health business
Animal Health sales increased 8% to $6.35 billion. Livestock and companion-animal products create exposure to markets with different demand drivers from human pharmaceuticals.
5. Global commercial capabilities
Merck sells medicines, vaccines and animal-health products worldwide. Global regulatory, manufacturing and distribution capabilities allow successful innovations to reach large patient and customer populations.
For management’s strategic response, see our Merck Business Strategy 2026.
Weaknesses
1. Extreme KEYTRUDA concentration
KEYTRUDA represented approximately 49% of total 2025 sales. Any major change in exclusivity, safety, competition or treatment standards could therefore have an unusually large financial impact.
2. GARDASIL sales decline
GARDASIL/GARDASIL 9 revenue fell 39% to $5.23 billion in 2025. The $3.35 billion decline materially offset growth across other products.
3. High-risk R&D economics
Merck spends billions before knowing whether candidates will succeed clinically or commercially. Even a large pipeline can experience failures that generate no product revenue.
4. Dependence on patent protection
Like other innovative pharmaceutical companies, Merck relies on patents and regulatory exclusivity. Generic or biosimilar competition can rapidly erode mature franchises.
5. Complex portfolio management
Human pharmaceuticals, vaccines and Animal Health require different development, manufacturing and commercial capabilities. Portfolio breadth increases organizational and capital-allocation complexity.
Opportunities
For external factors behind these opportunities, read our Merck PESTEL Analysis 2026.
1. WINREVAIR expansion
WINREVAIR sales rose to $1.44 billion from $419 million. Continued uptake and lifecycle development could establish cardiopulmonary disease as a major growth platform.
2. New oncology franchises
Welireg, alliance products and pipeline programs can build on Merck’s oncology infrastructure while reducing the proportion of oncology revenue dependent solely on KEYTRUDA.
3. Vaccine portfolio renewal
CAPVAXIVE and future vaccine programs can offset pressure on mature franchises. Successful launches could rebuild vaccines as a stronger source of growth.
4. External innovation and acquisitions
Merck can use its financial scale to acquire or partner for promising science, accelerating portfolio diversification beyond what internal discovery alone can provide.
5. Animal Health growth
Livestock revenue grew 13% in 2025 and companion-animal revenue 2%. Continued product innovation can expand a business already generating more than $6 billion annually.
Threats
1. KEYTRUDA loss of exclusivity
The eventual erosion of KEYTRUDA is Merck’s most consequential long-term risk because no other product currently approaches its $31.64 billion revenue scale.
2. Pharmaceutical pricing pressure
Governments and payers seek to control medicine spending. Pricing restrictions or reimbursement pressure can reduce returns even for clinically successful therapies.
3. Clinical and regulatory failures
Late-stage candidates can fail efficacy or safety requirements after substantial investment. Delayed approvals could also weaken Merck’s portfolio transition timeline.
4. Rapid competitive innovation
Oncology and other therapeutic markets evolve quickly. Better mechanisms, combinations or treatment modalities can take share before formal patent expiry.
5. Vaccine demand volatility
Vaccines can be affected by public-health recommendations, government purchasing, inventory and geographic demand. GARDASIL’s 2025 decline demonstrates this volatility.
Merck’s alliance portfolio is another strength because it broadens the oncology and hematology offering without requiring sole ownership of every asset. Lynparza, Lenvima and Reblozyl generated meaningful alliance revenue in 2025 and deepen relationships with specialist customers.
Geographic breadth is also valuable. Approximately $28.5 billion of 2025 sales came from international markets, reducing dependence on a single national health system even though the United States remains the largest market.
The principal weakness is not merely KEYTRUDA concentration but the timing mismatch inherent in replacing it. New products need years of development and commercialization before reaching blockbuster scale, so pipeline success must occur well before major revenue erosion begins.
Vaccine volatility adds another weakness. GARDASIL remains a large product despite its decline, meaning changes in vaccination patterns can materially affect consolidated growth. The business needs newer vaccine franchises to offset this variability.
CAPVAXIVE’s growth creates an opportunity to strengthen Merck’s pneumococcal position. Successful uptake can diversify vaccine revenue and demonstrate that the company can build new franchises even while older vaccine demand changes.
Merck’s oncology ecosystem also creates opportunities beyond KEYTRUDA. Existing development expertise can support Welireg, alliance assets and future candidates, allowing the company to reuse specialist capabilities across multiple therapies.
Acquisition competition is a threat because many large pharmaceutical companies are seeking external growth assets simultaneously. Bidding pressure can increase valuations, making disciplined scientific and financial assessment essential.
Manufacturing disruption is another threat. Vaccines and biologics require specialized production, and quality problems can constrain supply for extended periods. Redundant capacity and robust quality systems therefore protect both revenue and patient access.
Foreign-exchange movements can add reported volatility because more than 40% of sales are generated internationally. Currency does not determine underlying product demand, but it can affect reported revenue and earnings.
Overall, Merck’s SWOT profile is defined by exceptional current oncology strength paired with a time-sensitive diversification challenge. The company has substantial scientific and financial resources, but those resources need to translate into several large new franchises before concentration becomes a larger constraint.
Merck’s vaccine manufacturing expertise is another strength. Vaccines require specialized development and production capabilities that create barriers to entry. This infrastructure can support new launches such as CAPVAXIVE as the portfolio evolves.
Another weakness is that total 2025 sales grew only about 1% despite strong performance from several new products. The GARDASIL decline illustrates how difficult it can be for smaller launches to offset weakness in an established multi-billion-dollar franchise.
Merck also faces high fixed scientific costs. Approximately $15.8 billion of R&D spending is essential for future growth, but the company cannot know in advance which programs will generate attractive returns. Maintaining productivity at this spending scale is a continuing management challenge.
Formulation innovation creates an opportunity around established assets. KEYTRUDA QLEX can offer a different administration route, demonstrating how Merck can extend franchises through delivery innovation as well as new indications.
Cardiometabolic and respiratory disease can become a meaningful diversification platform if WINREVAIR and future pipeline assets continue scaling. A strong second or third therapeutic pillar would reduce dependence on oncology.
Merck can also use its global commercial network to accelerate successful launches internationally. Once a product has strong evidence, established regulatory and distribution capabilities can help convert approvals across countries into revenue.
Pricing pressure is especially important because high-value oncology products contribute so much revenue. Even before patent expiry, payer negotiations or policy changes can affect realized economics across large patient populations.
Clinical competition may also reduce revenue before legal exclusivity ends. Oncology treatment standards evolve through new combinations and mechanisms, so KEYTRUDA and other products need continued evidence generation to preserve their roles.
Supply risk can become particularly acute for vaccines, where manufacturing is complex and public-health demand can shift. Capacity planning must balance reliable supply with the possibility of volatile geographic demand.
The company’s financial resources give it many strategic options, but optionality itself can become a risk if acquisitions are pursued primarily to fill an anticipated revenue gap. Discipline matters most when management feels urgency to diversify.
Merck’s strongest opportunity is therefore not one product but a portfolio transition. Several successful launches across oncology, cardiopulmonary disease, vaccines and other areas would make the eventual KEYTRUDA transition much more manageable.
Another opportunity lies in alliance economics. Partnerships can give Merck exposure to successful therapies while sharing development or commercialization responsibilities. This can increase the number of scientific opportunities pursued without requiring sole ownership of every program.
Merck’s international footprint also provides diversification across health systems. Different countries may adopt products at different rates, allowing successful therapies to generate multiple geographic growth waves after initial approvals.
However, geographic breadth introduces currency and reimbursement complexity. International sales can grow operationally while reported results are affected by exchange rates, and government pricing can limit revenue per patient relative to the United States.
The Animal Health portfolio provides a further opportunity to compound through innovation. Growth in livestock and companion animals can support reinvestment into new veterinary medicines, vaccines and technologies, creating a self-reinforcing platform separate from human health.
The greatest strategic threat remains a timing gap between current blockbuster erosion and replacement growth. Even scientifically successful products may take years to reach commercial scale, making late pipeline setbacks particularly costly as KEYTRUDA approaches later lifecycle stages.
Source: Merck & Co., Inc., 2025 Annual Report / Form 10-K.
